Full Text View
Tabular View
No Study Results Posted
Related Studies
A Phase 4 Study to Determine Dosing of Hectorol® Capsules When Converting From Zemplar® Injection
This study has been completed.
Study NCT00463021   Information provided by Genzyme

First Received on April 18, 2007.   Last Updated on July 30, 2009   History of Changes
Related Studies can be found by searching for the Conditions, Interventions, and Sponsors found in this study:
Conditions listed in this trial
Secondary Hyperparathyroidism
Additional conditions recognized in this trial
Hyperparathyroidism
Hyperparathyroidism, Secondary
Renal Insufficiency, Chronic
More general conditions related to this trial
Endocrine System Diseases
Kidney Diseases
Parathyroid Diseases
Renal Insufficiency
Urologic Diseases
Interventions listed in this trial
Hectorol (doxercalciferol capsules)
Zemplar (paricalcitol injection)
Additional drug interventions recognized in this trial
1 alpha-hydroxyergocalciferol
Ergocalciferols
More general drug interventions related to this trial
Bone Density Conservation Agents
Growth Substances
Micronutrients
Pharmacologic Actions
Physiological Effects of Drugs
Vitamins
Sponsors listed in this trial
Genzyme


Contact Help Desk
Lister Hill National Center for Biomedical Communications,  U.S. National Library of Medicine,
U.S. National Institutes of Health,  U.S. Department of Health & Human Services,
USA.gov,  Copyright,  Privacy,  Accessibility,  Freedom of Information Act

U.S. National Institutes of Health U.S. National Library of Medicine U.S. Department of Health & Human Services